Announced Date: 2023-02-01 (February 1, 2023)
Asset Name: CB06-036（CB06）
Licensor: Shanghai Zhimeng Biopharma (China)
Licensee (Buyer): GSK（UK）
.
Asset Modality: Small Molecule, oral
Asset Target: TLR8 agonist
Potential Indication: treatment of HBV
Current Stage: Phase I clinical trial , China/US
.
Scope of Authority:
In December 2022, Zhimeng Biopharma entered into a Global Exclusive license agreement with GSK for CB06, a TLR8 agonist. Subject to successful completion of phase I, the agreement will allow GSK to develop, manufacture and commercialise CB06 for the treatment of HBV. If successful, CB06 could be used in combination, or as a sequential treatment with bepirovirsen, to potentially deliver a functional cure in more HBV patients.
.
Payment Detail:
Undisclosed
.
Link:
